PRS4 Evidence Synthesis of Association of HLA-B*1502 Allele and Carbamazepine -Induced Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review

Tangamornsuksan, Wimonchat; Chaiyakunapruk, Nathorn; Somkrua, Ratchadaporn; Lohitnavy, Manupat; Tassaneeyakul, Wichittra

doi:10.1016/j.jval.2012.08.225

Cited by 36 publications

(51 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strength of such associations has led to the recommendation to screen for this variant in patients with Asian ancestry before starting treatment [46,47]. However, other studies have failed to find such associations in Japan [48,49] and Europe [50,51].…”

Section: Anticonvulsantsmentioning

confidence: 99%

Update on the Genetic Basis of Drug Hypersensitivity Reactions

Jurado‐Escobar¹,

Perkins²,

García‐Martín³

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Drug hypersensitivity reactions (DHRs) are unpredictable, complex responses to medicines in predisposed individuals. They represent a major health problem owing to the number of patients affected and the severity of the clinical conditions they can induce. In addition to environmental factors, the underlying mechanisms of DHRs are also influenced by genetic factors, although considerable gaps remain in our knowledge. Therefore, further study of the genetics of DHRs is necessary to shed light on their underlying mechanisms. In this manuscript, we provide an update on the genetic basis of the most frequent types of DHRs, including those mediated by immunological and nonimmunological mechanisms. For the first group, we will focus on immediate reactions to β-lactam antibiotics, which are associated mainly with the IgE pathway (IL13, IL4R, LGALS3, and NOD2) and antigen presentation (HLA-DRA), and nonimmediate reactions to allopurinol, anticonvulsants, antibiotics, and antiretrovirals, which are often associated with polymorphisms in the HLA system. For the second group, we will focus on nonsteroidal anti-inflammatory drugs, which are mostly associated with genetic variants in enzymes and receptors from the arachidonic acid pathway (eg, ALOX5, ALOX5AP, PTGDR, and CYSLTR1). The information provided here will be of interest for medical practitioners from a range of disciplines who come across these reactions in their clinical practice, as well as for allergologists. Key words: Drug hypersensitivity. Immunologically-mediated reactions. Cross-hypersensitivity. Single-nucleotide polymorphisms. Genomewide association study. ResumenLas reacciones de hipersensibilidad a fármacos (RHFs) son respuestas no predecibles que se producen en algunos sujetos y que representan un serio problema de salud pública debido al número de pacientes implicados y a su potencial gravedad. Además de factores ambientales, en estas reacciones también participan factores genéticos, cuya influencia está, en la mayoría de los casos, aún por dilucidar. En este manuscrito describiremos la información disponible sobre la base genética de los tipos más frecuentes de RHFs, tanto de las mediadas inmunológicamente como de aquellas en las que no se requiere reconocimiento antigénico. En el primer grupo nos ocuparemos de las reacciones inmediatas a antibióticos β-lactámicos, que han sido asociadas con variantes relacionadas con la IgE (IL13, IL4R, LGALS3 y NOD2) y la presentación antigénica (HLA-DRA), y de las reacciones no inmediatas a diferentes grupos de medicamentos (alopurinol, anticonvulsivos, antibióticos y antiretrovirales), relacionadas fundamentalmente con polimorfismos en el sistema HLA. En el segundo grupo nos centraremos en las reacciones inducidas por antiinflamatorios no esteroideos (AINE), que han sido asociadas básicamente con variantes en enzimas y receptores de la vía del ácido araquidónico (ALOX5, ALOX5AP, PTGDR y CYSLTR1, entre otros). Esta revisión puede ser de interés no sólo para alergólogos, sino para los profesionales de otras ...

show abstract

Section: Anticonvulsantsmentioning

confidence: 99%

Update on the Genetic Basis of Drug Hypersensitivity Reactions

Jurado‐Escobar¹,

Perkins²,

García‐Martín³

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…Notably, we found associations between HLA-B*1502 and OXC-induced SJS in both general population control and OXC-tolerant groups Other OXC-induced pathologies such as TEN are not well studied and, to our knowledge, are confined to studies where SJS and TEN data were pooled (7,11,25). Thus, based on current findings and the previous studies, subjects harboring the allele might develop TEN when given OXC.…”

Section: Discussionmentioning

confidence: 83%

“…Several studies suggested that most cADRs caused by epileptic drugs (e.g., CBZ, phenytoin, lamotrigine) are drug-specific immune responses through human leukocyte antigens (HLAs) (7,8). HLA is a gene group encoding the major histocompatibility complex (MHC) located on chromosome 6 in humans (9, 10).…”

Section: Introductionmentioning

confidence: 99%

Association Between HLA genotypes and Oxcarbazepine-induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis

2018

View full text Add to dashboard Cite

-PURPOSE:To systematically review and quantitatively synthesize associations between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions (OXC-cADRs), including StevensJohnson syndrome (SJS) and maculopapular rash. METHODS: Studies investigating associations between HLA genotypes and OXC-cADRs were systematically searched irrespective of language, in PubMed, HuGENet (Human Genome Epidemiology Network), and the Cochrane Library from their inception until January, 2017. Inclusion criteria were studies investigating associations between HLA genotypes and OXCcADRs that reported sufficient data for calculating the frequency of HLA genotype carriers among cases and controls. Overall odds ratios (ORs) with corresponding 95%CIs were calculated using a random-effects model to determine the association between HLA genotypes and OXC-cADRs. RESULTS: The initial searches identified 91 articles, of which 6 studies met the selection criteria. . CONCLUSIONS: Strong associations between the HLA-B*1502 and OXC-cADRs (SJS and maculopapular rash) were found in both controls from general population and OXC-tolerant groups. There was also an association between HLA-B*3101 and OXCinduced maculopapular rash. For patient safety, genetic screening especially for HLA-B*1502 prior to OXC therapy at least in these closely related ethnicities is warranted. Further studies need to better define other ethnicities at risk and a wider range of MHC gene subtypes.

show abstract

“…The latter association was first demonstrated in Han Chinese patients, in which 44 with CBZ-induced SJS/TEN were positive for HLA-B*15:02 compared to 3% in the CBZ-tolerant cohort (odds ratio 2504) (7). Subsequent studies have also confirmed this association in Thai, Korean, Malaysian and Indian populations (8). As a result of this suggestive results, the US Food and Drug Administration has recommended prescreening testing for HLA-B*15:02 allele before prescribing CBZ in the ethnic groups at risk (9).…”

Section: Introductionmentioning

confidence: 81%